Myeloid Entered into an Exclusive Option & Research Collaboration with Prime Medicine to Develop and Accelerate RetroT Technology for Human Diseases
Shots:
- Myeloid received $45M up front & is eligible to receive milestones & option exercise fees along with sales-based royalties. Prime will get an exclusive option to gain control of the intellectual property estate & expand its existing platform
- The companies focus on accelerating the development of Myeloid's RNA-based, retrotransposon-mediated gene-insertion technology for gene editing & complementary to Prime Editing
- The collaboration will optimize Myeloid's RetroT technology to deliver genetic sequences & integration enzymes in a single mRNA strand for gene editing. If successful, this technology can be used to simplify the delivery of ex vivo & in vivo cell therapies for human diseases
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
